Business graduate from a working man's school after several years of stop and start and working full time and raising two families. Began playing with options in 2006, not very timely unless you can short with big bankroll, and have been doing so since, with more of an investment perpective while running my wife's rollover the last several months. Like mostly dividend paying, L/T record of growth, with a little spec including first mover/ biotech break through type companies that have a tremendous long term possibilities.
I'm an individual investor, I read up on companies before I decide to invest, I make my own decisions so that I can only blame myself for any mistakes I may make! I do find it strange when people on these advice sites run down companies that they have no investment in, and rarely give a positive as well as negatives. It makes me wonder if they have an ulterior motive for running down companies that they say they have no interests in! I think when an investor with a following has a bad beat, they look for excuses as to why this happened, when instead, they should take it on the chin admit they got it wrong and move on! These investments can go down as well as up! That's what I read everywhere! That's the only thing that is true!
I graduated from Boston University in 1981 with a BA in Finance. From 1983-1997, I was a spot currency trader on the desks of several European banks in NYC. Since 1997, I have been trading from home. I consider myself to be a student of markets, and market history. I believe so much can be learned from history, and examining the facts. I try never to make an assertion about economics or markets, without it being fact-based and not simply an opinion.
Investor since a decade, who invests cent percent of investment capital into equities and does his own research to chose long term winners, who will also be a decent bet for the medium term.
I manage the following, where you can follow me and interact at (free forever):
i. A Facebook page which conveys relevant business news, market information, views and insights ( facebook.com/WallStreetGuru )
ii. A Twitter handle where I share my picks, offer 'blatant' view on market events and answer questions: @ABraveBull
iii. A blog that I write on significant market events (http://www.sunnygoklani.com/brave-bull-updates).
I believe knowledge is cumulative and everyone has a unique contribution to make. We all collectively make this world a better place to co-exist.
Learning as I go. My investing experience is limited, but I believe that biotechnology/pharmaceuticals hold the key to the best returns in the next 5-10 years. Targeted therapy, monoclonal antibodies, and genetic treatment tailoring are the future of medicine.
I am a practicing Army Physician (Diagnostic Radiologist). My professional interests include neuroradiology, brain tumors, head and neck cancer, functional MRI, and emerging tagged imaging agents. I intend to apply for a fellowship in neuroradiology this coming Summer. As such, I intend my writing to be speculative, but directed by science and my experiences thus far in medicine with an optimistic essence.
CPA, Arthur Andersen
financial analyst, Equity Research, financial sector, Salomon Brothers
Institutional Equity Research Sales, Goldman Sachs
Private Wealth Manager, Goldman Sachs, Deutsche Bank, Credit Suisse and JP Morgan
MBA, Columbia Business School, Finance
BS, Univ of MD, College Park, MD, Accounting
Dallas currently owns and operates as CEO an Austin-based enterprise consulting firm that specializes in private company lifecycle management, up to and including taking companies public, and in helping consult publicly traded companies ranging in market cap from $100 million to $500 million. He has a specialization in deal flow management and is often the referring and closing source of Joint Ventures and broader M&A. Dallas often works directly with management teams and Boards of microcap and stressed equity companies in which he or members of his professional network are heavily invested. This includes helping with overall strategy, helping with capital structure management, helping facilitate liquidity, helping facilitate Joint Ventures and broader M&A, and helping restructure the business segments if necessary. Recently Dallas has been interviewed by The Pittsburgh Business Times, The Banker, Columbus Business First, Houston Business Journal, The Deal, Energy Intelligence, and his tweets have been used by CNBC to highlight hot button issues regarding Carl Icahn, Bill Ackman, Nelson Peltz’s takeover attempts at DuPont, etc. Dallas has also been quoted and sourced to by StreetSweeper.org, Marcellus.com, MarcellusDrilling.com, Bakken.com, OilOnline.com, and other physical and online publications. "One place of great inefficiency is in the stressed equity markets – or the markets in which a company appears as bankruptcy or a breakup is inevitable. As equities become stressed they often sell down to absurd levels of value that present, should there be value to be unlocked, opportunities for “venture level” returns. These often range in the 3X-10X range. With my unique ability to actually improve business outcomes by working directly with a company and management/Board I’m in a position, should I view the underlying business as salvageable, to directly improve the long-term viability of the company. I am NOT simply an investor in these names but an acting consultant. This allows me to “overlay my network” and to move the company away from a stressed or defaulting outcome and into an outcome probability that allows the equity price to move substantially higher. Identifying these opportunities has generated shareholders and investors thousands of percentage points in aggregate and is something I’m often recognized by paying subscribers for."
Licensed Investment professional. Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business. Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon. Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private pooled investment partnership, Vasuda Life Sciences Fund. Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
Investor and trader that has been involved with trading equities for several years. Former business owner/investor that bought failing companies and turned them around and into profitable companies. Specialize in finding up and coming and possible turn around companies.
Ian Bezek worked for 3 years as an analyst at a New York-based hedge fund. He's currently living in Mexico, pursuing some entrepreneurial opportunities.
Feel free to contact him regarding investments, writing, or speaking opportunities.
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
I grew up in Philadelphia, PA attended the University of Colorado at Boulder where I studied anthropology and international business. After college, I moved to Vancouver BC and worked with the Finance Minister. I then moved to California and continued to cultivate my interest in politics, international business, and frequent flier miles. I worked with the Finance Minister of Panama and elsewhere in Latin America. I owe much of my success in life to my mentor and my 2-year-old son's godfather. I sincerely believe that the adoption of plant-based expression platforms can provide an element of stability to the global economy while providing significant health benefit.